MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma

Cisplatin-based chemotherapy is the primary treatment for metastatic bladder urothelial carcinoma. However, the response rate is only 40–65%. This study investigated the anti-tumor effect and underlying mechanisms of the combination of cisplatin and the NEDD8-activating enzyme inhibitor MLN4924 in h...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, I-Lin, Kuo, Kuan-Lin, Liu, Shing-Hwa-, Chang, Hong-Chiang, Hsieh, Ju-Ton, Wu, June-Tai, Chiang, Chih-Kang, Lin, Wei-Chou, Tsai, Yu-Chieh, Chou, Chien-Tso, Hsu, Chen-Hsun, Pu, Yeong-Shiau, Shi, Chung-Sheng, Huang, Kuo-How
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4655337/
https://www.ncbi.nlm.nih.gov/pubmed/26592553
http://dx.doi.org/10.1038/srep16948

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4655337/
https://www.ncbi.nlm.nih.gov/pubmed/26592553
http://dx.doi.org/10.1038/srep16948

Ejemplares similares